Melanoma arising in a Giant congenital melanocytic nevus: two case reports

Bibliographic Details
Title: Melanoma arising in a Giant congenital melanocytic nevus: two case reports
Authors: Tatiana S. Belysheva, Yana V. Vishnevskaya, Tatiana V. Nasedkina, Marina A. Emelyanova, Ivan S. Abramov, Kristina V. Orlova, Ludmila N. Lubchenko, Igor A. Utyashev, Marina B. Doroshenko, Lev V. Demidov, Mamed D. Aliev
Source: Diagnostic Pathology, Vol 14, Iss 1, Pp 1-9 (2019)
Publisher Information: BMC, 2019.
Publication Year: 2019
Collection: LCC:Pathology
Subject Terms: Giant congenital melanocytic nevus, Melanoma, Neurocutaneous melanosis, Genetic analysis, NRAS mutation, Infants, Pathology, RB1-214
More Details: Abstract Background A giant congenital melanocytic nevus (GCMN) is found in 0.1% of live-born infants. If present, the lesion has a chance of about 6% to develop into malignant melanoma. Both children and adults can be affected by malignant melanoma arising in a giant congenital nevus. Up to 95% of GCMNs harbor NRAS mutations, and mutations in the BRAF, MC1R, TP53, and GNAQ genes have also been described. The individualization of therapy is required, but diagnostic and prognostic criteria remain controversial. Case presentations We report two cases: 1) melanoma arising in a giant congenital nevus during the first month of life complicated with neurocutaneous melanosis (NCM), and 2) melanoma arising in a giant congenital nevus during the first 6 months of life. Pathology, immunohistochemistry, and genetic analyses of tumor tissue were performed. The first case revealed only a non-pathogenic P72R polymorphism of the TP53 gene in the homozygote condition. For the second case, a Q61K mutation was detected in the NRAS gene. Conclusion Malignant melanoma associated with GCMN is rare and therefore poorly understood. Outcomes have been linked to the stage at diagnosis, but no additional pathological prognostic factors have been identified. The most frequent genetic event in giant CMNs is NRAS mutations, which was discovered in one of our cases. To accumulate evidence to improve disease prognosis and outcomes, children with congenital melanocytic nevus should be included in a systemic follow-up study from birth.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1746-1596
Relation: http://link.springer.com/article/10.1186/s13000-019-0797-1; https://doaj.org/toc/1746-1596
DOI: 10.1186/s13000-019-0797-1
Access URL: https://doaj.org/article/ab9b7b4e1f8a40e1853614efbd30c4b6
Accession Number: edsdoj.b9b7b4e1f8a40e1853614efbd30c4b6
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:17461596
DOI:10.1186/s13000-019-0797-1
Published in:Diagnostic Pathology
Language:English